Publicaciones científicas

Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature

Miguel Barajas (a,b), Federico Franchi (a), Carlos Clavel (b), Xabier L. Aranguren (b), M. Gabriela Kramer (a), Gloria Abizanda (a), Juana Merino (c), Cristina Moreno (c), Leire Gárate (b), Anunciata Guitart (a), Iñigo Narvaiza (a), María Gutiérrez-Perez (b), Jose-Ignacio Riezu-Boj (a), Carmen Berasain (a), Jesús Prieto (a) and Felipe Prósper (b)
(a) Department of Medicine and Division of Hepatology and Gene Therapy, Clínica Universitaria/School of Medicine and Centre for Applied Medical Research (CIMA), University of Navarra, Spain
(b) Area of Hematology and Cell Therapy, Clínica Universitaria/School of Medicine and Centre for Applied Medical Research (CIMA), University of Navarra, Spain (c) Department of Immunology, Clínica Universitaria/School of Medicine, University of Navarra, Spain

Revista: Biochemical and Biophysical Research Communications

Fecha: 07-dic-2007

Inmunología e Inmunoterapia Hepatología Área de Terapia Celular

The use of stem cells as a vehicle of therapeutic genes is an attractive approach for the development of new antitumoral strategies based on gene therapy.

The aim of our study was to assess the potential of bone marrow-derived Multipotent Adult Progenitor Cells (rMAPCs) to differentiate in vitro and in vivo into endothelial cells and to be recruited to areas of tumor vasculogenesis. In vitro, rMAPCs obtained from Buffalo rats differentiated into cells expressing endothelial markers and demonstrated functional endothelial capacity. Intravenous injection of undifferentiated rMAPC transduced with a lentivirus expressing GFP in an orthotopic rat model of hepatocellular carcinoma, resulted in tumor recruitment of the injected cells and in vivo differentiation into endothelial cells in the tumor area with contribution to vasculogenesis.

In summary, our results suggest that rMAPCs can be efficiently recruited by vascularized tumors and differentiate to endothelium and thus may represent a useful vehicle for delivery of therapeutic genes to sites of active tumor neovascularization.

CITA DEL ARTÍCULO  Biochem Biophys Res Commun. 2007 Dec 7;364(1):92-9

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra